🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER-2 Positive Advanced Solid Tumors

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569n/a1 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Trastuzumab deruxtecan (DS-8201a) FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors NCT06241456Phase 114 sites📍 Gilbert📍 La Jolla📍 New Haven Fate Therapeutics · Tests: FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155EARLY Phase 15 sites📍 Kingswood📍 Macquarie Park📍 Wollongong Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD202 Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors NCT06950086Phase 1, Phase 22 sites📍 Shanghai📍 Shanghai TYK Medicines, Inc · Tests: TYK-00540 First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors NCT05461768Phase 17 sites📍 Fuzhou📍 Dongguan📍 Guangdong Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites📍 Boston📍 St Louis National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors NCT06822998EARLY Phase 11 site📍 Chengdu HighField Biopharmaceuticals Corporation · Tests: HF50 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) NCT07486089Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844Phase 1, Phase 215 sites📍 Newport Beach📍 San Francisco📍 New Haven Ensem Therapeutics · Tests: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination… A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites📍 La Jolla📍 Los Angeles📍 Aurora Iambic Therapeutics, Inc · Tests: IAM1363 A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites📍 Fort Worth📍 Houston📍 San Antonio Antares Therapeutics, Inc · Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer NCT07462650Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DUO-CAR-NK-CEA/GCC (IV) HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors NCT05681650Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide, Fludarabine A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors NCT05150691Phase 1, Phase 2102 sites📍 Cerritos📍 Los Angeles📍 San Diego DualityBio Inc. · Tests: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors NCT05957536Phase 19 sites📍 Stanford📍 Boston📍 New York D3 Bio (Wuxi) Co., Ltd · Tests: D3L-001 Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors NCT03740256Phase 11 site📍 Houston Baylor College of Medicine · Tests: CAdVEC Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites📍 Boston📍 Nashville📍 Adelaide Yuhan Corporation · Tests: YH32367 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559Phase 260 sites📍 Phoenix📍 Tucson📍 Duarte ALX Oncology Inc. · Tests: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917Phase 1, Phase 220 sites📍 Tucson📍 La Jolla📍 Los Angeles Aminex Therapeutics, Inc. · Tests: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148Phase 1, Phase 233 sites📍 Los Angeles📍 Fort Myers📍 Boston Novartis Pharmaceuticals · Tests: ECI830, ribociclib, fulvestrant A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors NCT06031584Phase 1, Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860Phase 22 sites📍 Jacksonville📍 Grand Forks Mayo Clinic · Tests: Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors NCT06658951NA1 site📍 Zhengzhou UTC Therapeutics Inc. · Tests: Anti-HER2 CAR-T cells The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy